ISIKOK-19

Product characterization, in vivo expansion, and persistence of CAR-T were published before (Erdogan et al, 2022).After a cyclophosphamide/fludarabine-containing lymphodepletion regimen, ISIKOK-19 CAR-T therapy was applied in three fractionated doses...P1 and P2 who had grade 2 CRS needed tocilizumab treatment. Immune effector cell-associated neurotoxicity syndrome (ICANS) was observed only in P4 as grade 2 and this patient recovered after dexamethasone treatment. Besides CRS and ICANS, P4 had hemolytic anemia in the 4th month of CAR-T therapy and recovered after daratumumab treatment.CAR-T was still detected in peripheral blood and CSF in P3 and P4 at 5 months and 6 months, subsequently... In conclusion, the administration of ISIKOK-19 CAR-T therapy in this small patient group with EMD achieved safety and efficacy outcomes. These preliminary results make us believe that ISIKOK-19 CAR-T constitutes a potential therapeutic option in such a high unmet medical need.

No abstract available

 A 22 years old male patient received anti CD-19 directed academic CAR-T cell (ISIKOK-19) infusion due to relapsed acute lymphoblastic leukemia following haploidentical stem cell transplantation from his mother.  Cold agglutinin mediated hemolytic anemia post CAR-T cell treatment is a complex entity with lack of evidence based treatment . Anti CD38 monoclonal antibody daratumumab induces rapidly depletion of antibody producing plasma cells and can be an option in steroid, IVIG and Rituximab refractory cold agglutinin mediated autoimmune hemolytic anemia in CAR-T cell patients.